John Oppenheimer on Muck Rack

John Oppenheimer

As seen in: MDPI, U.S. News and World Report, JAMA (The Journal of the American Medical Association), Medscape, The Lancet, Bloomberg Law, Healio, Healio Allergy/Asthma, Bisnow, Chest and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with John

Contact John, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Seattle 2026 CEO Market Kickoff

|
By John Oppenheimer
| Bisnow
Gain a forward-looking view of how capital and deal flow are shifting in Seattle and which submarkets are poised to accelerate or soften in 2026. • Explore how interest rates, inflation, macro forces, and policy shifts will influence development viability, underwriting, and risk assessments. • Understand how land use, permitting reform, zoning changes, and infrastructure investments are shaping the pipeline and where densification creates opportunity.
Open in Who Shared Issue with article?

Six-month asthma control score on mepolizumab predicts remission in eosinophilic asthma

|
By Isabella Hornick, Kristen Dowd , John Oppenheimer, Sarah Rhoads
| Healio Allergy/Asthma
Perspective Back to Top John J. Oppenheimer, MD While it is known that mepolizumab can induce remission on therapy in a subgroup of asthmatics and there are data indicating which asthmatics are likely to respond, this study adds to our ability to optimize care, demonstrating that ACQ-5 score at 6 months was the best predictor of achieving remission at 1 year.
Open in Who Shared Issue with article?

Depemokimab reduces severe asthma exacerbations by half with twice-yearly treatment

|
By Richard Gawel , Kristen Dowd , John Oppenheimer
| Healio Allergy/Asthma
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Depemokimab has high binding affinity and potency for IL-5. Eosinophils fell by 83% and 82% with treatment in the two trials. The treatment and placebo groups had similar rates and types of adverse events.
Open in Who Shared Issue with article?
See all 96 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with John

Contact John, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified